Genitourinary Cancers | Specialty

Advanced RCC Results Point to Potentially New Frontline Treatments

October 5th 2017

Michael R. Harrison, MD, discusses emerging data that are likely to impact the treatment landscape for patients with RCC.

Debating the True Benefit of Adjuvant TKIs in High-Risk RCC

October 4th 2017

Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.

Atezolizumab + Bevacizumab in Treatment-Naive mRCC

October 4th 2017

Sunitinib Before Cytoreductive Nephrectomy in mRCC

October 4th 2017

CABOSUN: Upfront Use of Cabozantinib for mRCC

October 4th 2017

CheckMate-214: Nivolumab/Ipilimumab for mRCC?

October 4th 2017

Dr. Uzzo on Unmet Needs in Kidney Cancer

October 4th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses pressing unmet needs for patients with kidney cancer.

Dr. Hoffman-Censits on Challenges With Sequencing for Urothelial Carcinoma

October 4th 2017

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

Phase III Data Show Benefit With Abiraterone in Castration-Sensitive Prostate Cancer

October 4th 2017

Tian Zhang, MD, discusses emerging results for patients with metastatic castration-sensitive prostate cancer.

Expert Highlights Biological Advancements in Bladder Cancer Field

October 3rd 2017

Brant Inman, MD, discusses the biology of bladder cancer, the evolving role of checkpoint inhibitors, and the future of chemotherapy in the disease.

Dr. Inman Discusses the Biology of Bladder Cancer

October 3rd 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the biology of bladder cancer.

Dr. Zhang on the Impact of the LATITUDE Study in Prostate Cancer

October 3rd 2017

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Dr. Zibelman on Determining Treatments for Patients with RCC

October 3rd 2017

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

Dr. Geynisman on Sequencing of Agents for Kidney Cancer

October 3rd 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Expert Discusses Optimizing Sequence of Non-Hormonal Therapy in mCRPC

October 3rd 2017

Daniel J. George, MD, discusses the major questions practitioners are asking regarding optimizing upfront therapy for patients with mCRPC.

Dr. Hoffman-Censits on Biomarker Development in Urothelial Carcinoma

September 29th 2017

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses biomarker development in the field of urothelial carcinoma.

Successful ESMO Studies to Likely Trigger Sequencing Shakeup in RCC

September 29th 2017

Rana R. McKay, MD, discusses the promising findings from the CheckMate-214 and CABOSUN studies in renal cell carcinoma.

Dr. Uzzo on the Guidelines for the Management of Kidney Cancer

September 28th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the guidelines for the treatment and management of patients with kidney cancer.

Dr. Plimack on Strategies for Developing Cure for Locally Advanced Urothelial Carcinoma

September 28th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses strategies for developing cures for patients with locally advanced urothelial carcinoma.

Bladder Cancer Paradigm Expanding to Include Immunotherapy Combos, Targeted Therapies

September 28th 2017

Terence Friedlander, MD, discusses the targeted therapies emerging in the field of bladder cancer, as well as immunotherapy combinations that are traveling through the pipeline.